302 related articles for article (PubMed ID: 17522330)
21. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
[TBL] [Abstract][Full Text] [Related]
22. Bile acid-mediated thrombospondin-1 induction in hepatocytes leads to transforming growth factor-beta-dependent hepatic stellate cell activation.
Myung SJ; Yoon JH; Gwak GY; Kim W; Yang JI; Lee SH; Jang JJ; Lee HS
Biochem Biophys Res Commun; 2007 Feb; 353(4):1091-6. PubMed ID: 17204245
[TBL] [Abstract][Full Text] [Related]
23. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
24. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
[TBL] [Abstract][Full Text] [Related]
25. SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.
Roth P; Kissel M; Herrmann C; Eisele G; Leban J; Weller M; Schmidt F
Clin Cancer Res; 2009 Nov; 15(21):6609-18. PubMed ID: 19825946
[TBL] [Abstract][Full Text] [Related]
26. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
Gorelik L; Flavell RA
Nat Med; 2001 Oct; 7(10):1118-22. PubMed ID: 11590434
[TBL] [Abstract][Full Text] [Related]
27. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
28. Bikunin down-regulates heterodimerization between CD44 and growth factor receptors and subsequently suppresses agonist-mediated signaling.
Wakahara K; Kobayashi H; Yagyu T; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
J Cell Biochem; 2005 Apr; 94(5):995-1009. PubMed ID: 15597342
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
30. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β.
Lohr J; Ratliff T; Huppertz A; Ge Y; Dictus C; Ahmadi R; Grau S; Hiraoka N; Eckstein V; Ecker RC; Korff T; von Deimling A; Unterberg A; Beckhove P; Herold-Mende C
Clin Cancer Res; 2011 Jul; 17(13):4296-308. PubMed ID: 21478334
[TBL] [Abstract][Full Text] [Related]
31. TGF-β as a therapeutic target in high grade gliomas - promises and challenges.
Joseph JV; Balasubramaniyan V; Walenkamp A; Kruyt FA
Biochem Pharmacol; 2013 Feb; 85(4):478-85. PubMed ID: 23159669
[TBL] [Abstract][Full Text] [Related]
32. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
33. Strategies for TGF-beta modulation: a review of recent patents.
Bonafoux D; Lee WC
Expert Opin Ther Pat; 2009 Dec; 19(12):1759-69. PubMed ID: 19939191
[TBL] [Abstract][Full Text] [Related]
34. SB-431542, a transforming growth factor beta inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion.
Waghabi MC; Keramidas M; Calvet CM; Meuser M; de Nazaré C Soeiro M; Mendonça-Lima L; Araújo-Jorge TC; Feige JJ; Bailly S
Antimicrob Agents Chemother; 2007 Aug; 51(8):2905-10. PubMed ID: 17526757
[TBL] [Abstract][Full Text] [Related]
35. Pirfenidone inhibits TGF-beta expression in malignant glioma cells.
Burghardt I; Tritschler F; Opitz CA; Frank B; Weller M; Wick W
Biochem Biophys Res Commun; 2007 Mar; 354(2):542-7. PubMed ID: 17234158
[TBL] [Abstract][Full Text] [Related]
36. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.
Laping NJ; Everitt JI; Frazier KS; Burgert M; Portis MJ; Cadacio C; Gold LI; Walker CL
Clin Cancer Res; 2007 May; 13(10):3087-99. PubMed ID: 17505012
[TBL] [Abstract][Full Text] [Related]
37. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
38. LPS-induced up-regulation of TGF-beta receptor 1 is associated with TNF-alpha expression in human monocyte-derived macrophages.
Chen Y; Kam CS; Liu FQ; Liu Y; Lui VC; Lamb JR; Tam PK
J Leukoc Biol; 2008 May; 83(5):1165-73. PubMed ID: 18252868
[TBL] [Abstract][Full Text] [Related]
39. Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line.
Lee GT; Hong JH; Kwak C; Woo J; Liu V; Lee C; Kim IY
Cancer Res; 2007 Jul; 67(14):6717-24. PubMed ID: 17638882
[TBL] [Abstract][Full Text] [Related]
40. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
